lupus

  1. Chandelier

    Trial Report Low dose IL-2 therapy restores regulatory T cells in patients w/ systemic lupus erythematosus in a dose-dependent manner: phase IIb trial, 2026, Zhang

    Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trial Abstract Low-dose interleukin 2 (Ld-IL2) has shown therapeutic effects in autoimmune diseases, particularly systemic lupus erythematosus (SLE), yet...
  2. Liii

    Lupus Diagnosis: Process and Patient Experience

    This is a poster I think, about a survey by Lupus Foundation of America. I don't find a full article anywhere. Authors: Daly R, Partovi R. Background/Purpose: Delays in lupus diagnosis and misdiagnosis are sources of concern, as uncontrolled disease activity and early damage can increase...
  3. Sly Saint

    Groundbreaking immune therapy sees lupus patients go into remission

    https://www.independent.co.uk/life-style/health-and-families/health-news/lupus-treatment-remission-cart-cell-therapy-nhs-b2994527.html
  4. InitialConditions

    Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus, Younis et al., 2025

    Editor’s Summary Epstein-Barr virus (EBV) has been making waves as a candidate driver of diseases like multiple sclerosis and Long Covid. It has also long been linked to systemic lupus erythematosus (SLE), although the “why” behind this link has not been defined. Here, Younis et al. provide...
  5. Sly Saint

    Article: Engineered CAR-NK cells could evade immune rejection and target cancer more effectively

    https://medicalxpress.com/news/2025-10-car-nk-cells-evade-immune.html
  6. OrganicChilli

    Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus

    Abstract A woman with aggressive refractory systemic lupus erythematosus was treated with a short course of the bispecific antibody teclistamab (anti–B-cell maturation antigen and anti-CD3) and had a drug-free complete remission. Link Full article if you follow the link in the comments (not...
  7. SNT Gatchaman

    Common Variants within MECP2 Confer Risk of Systemic Lupus Erythematosus, 2008, Sawalha et al.

    Common Variants within MECP2 Confer Risk of Systemic Lupus Erythematosus Amr H. Sawalha; Ryan Webb; Shizhong Han; Jennifer A. Kelly; Kenneth M. Kaufman; Robert P. Kimberly; Marta E. Alarcón-Riquelme; Judith A. James; Timothy J. Vyse; Gary S. Gilkeson; Chan-Bum Choi; R. Hal Scofield; Sang-Cheol...
  8. SNT Gatchaman

    Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to [SLE], 2009, Webb+

    Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus Ryan Webb; Jonathan D. Wren; Matlock Jeffries; Jennifer A. Kelly; Kenneth M. Kaufman; Yuhong Tang; Mark...
  9. forestglip

    Diagnostic overshadowing in systemic lupus erythematosus (SLE): A qualitative study, 2025, Harwood et al

    Diagnostic overshadowing in systemic lupus erythematosus (SLE): A qualitative study Rupert Harwood, Chris Wincup, David D’Cruz, and Melanie Sloan [Line breaks added] Objectives SLE diagnostic journeys can be protracted, with negative impacts on long-term health. This study explored the role...
  10. jnmaciuch

    Timeline of interferon, autoantibodies, and autoimmune disease development

    Posting several links exploring temporal dynamics between interferon, autoantibodies, and autoimmune diseases (primarily lupus). (Review) Emerging concepts of type I interferons in SLE pathogenesis and therapy Note: SLE = systemic lupus erythematosus Links to references are active in the...
  11. Sly Saint

    Article: Simple blood test offers new hope to lupus patients

    Simple blood test offers new hope to lupus patients
  12. forestglip

    Review Ignored, Dismissed, and Minimized: Understanding the Harmful Consequences of Invalidation in Health Care [...], 2025, Bontempo et al

    Ignored, Dismissed, and Minimized: Understanding the Harmful Consequences of Invalidation in Health Care—A Systematic Meta-Synthesis of Qualitative Research Allyson C. Bontempo, John M. Bontempo, Paul R. Duberstein [Line breaks added] Abstract The upsurge in the prevalence of contested...
  13. H

    Is it useful to compare CBT in SLE and ME/CFS?

    I’ve been wondering whether it’s helpful to compare how cognitive behavioral therapy (CBT) is used in systemic lupus erythematosus (SLE) and in ME/CFS. Both are complex, multifactorial chronic illnesses. Adverse childhood experiences are also thought to increase the risk of developing SLE, and...
  14. forestglip

    Correlation of Interferons and Autoimmune Aspects in Long COVID-19 Patients, 2025, Hattori et al

    Correlation of Interferons and Autoimmune Aspects in Long COVID-19 Patients Fumiyuki Hattori, Junji Nishiyama, Hideaki Hasuo [Line break added] Abstract Long COVID, or post-acute sequelae of COVID-19 (PASC), represents a major global health challenge, with its underlying mechanisms remaining...
  15. forestglip

    Exploring the shared mechanism of fatigue between [lupus] and [ME/CFS]: monocytic dysregulation..., 2024, Zheng et al

    Exploring the shared mechanism of fatigue between systemic lupus erythematosus and myalgic encephalomyelitis/chronic fatigue syndrome: monocytic dysregulation and drug repurposing Daisi Zheng, Xiaolong Li, Qingmiao Zhu, Zhiyan Huang, Peicheng Wang, Ting Zhao [Provisionally accepted] Edit: Now...
  16. Joan Crawford

    Epstein–Barr virus as a potentiator of autoimmune diseases

    Epstein–Barr virus as a potentiator of autoimmune diseases William H. Robinson, Shady Younis, …Tobias V. Lanz Show authors Nature Reviews Rheumatology (2024)Cite this article Metricsdetails Abstract The Epstein–Barr virus (EBV) is epidemiologically associated with development of autoimmune...
  17. SNT Gatchaman

    Interferon gene expression declines over time post-COVID infection and in long COVID patients, 2024, Gómez-Carballa et al.

    Interferon gene expression declines over time post-COVID infection and in long COVID patients A. Gómez-Carballa; S. Pischedda; J. Pardo-Seco; J. Gómez-Rial; F. Martinón-Torres; A. Salas BACKGROUND Interferons (IFNs) represent a first-line defense against viruses and other pathogens. It has been...
  18. SNT Gatchaman

    Interferon subverts an AHR–JUN axis to promote CXCL13+ T cells in lupus, 2024, Law et al.

    Interferon subverts an AHR–JUN axis to promote CXCL13+ T cells in lupus Law, Calvin; Wacleche, Vanessa Sue; Cao, Ye; Pillai, Arundhati; Sowerby, John; Hancock, Brandon; Horisberger, Alice; Bracero, Sabrina; Skidanova, Viktoriya; Li, Zhihan; Adejoorin, Ifeoluwakiisi; Dillon, Eilish; Benque, Isaac...
  19. Sly Saint

    Drug used by millions for common condition could end pain for arthritis sufferers

    Researchers found medication that controls blood sugar levels in type 2 diabetes can also help patients with certain auto-immune diseases such as Lupus and arthritis Drug used by millions for common condition could end pain for arthritis sufferers - Mirror Online
  20. Andy

    Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares, 2023, Azzouz et al

    Objective Whereas genetic susceptibility for systemic lupus erythematosus (SLE) has been well explored, the triggers for clinical disease flares remain elusive. To investigate relationships between microbiota community resilience and disease activity, we performed the first longitudinal...
Back
Top Bottom